Analysts expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to report $-0.57 EPS on March, 19.They anticipate $0.10 EPS change or 21.28% from last quarter’s $-0.47 EPS. After having $-0.53 EPS previously, Syros Pharmaceuticals, Inc.’s analysts see 7.55% EPS growth. The stock decreased 0.77% or $0.08 during the last trading session, reaching $10.31. About 102,466 shares traded. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Lyon Street Capital Llc decreased Axogen Inc (AXGN) stake by 29.01% reported in 2017Q3 SEC filing. Lyon Street Capital Llc sold 87,335 shares as Axogen Inc (AXGN)’s stock rose 35.94%. The Lyon Street Capital Llc holds 213,749 shares with $4.14 million value, down from 301,084 last quarter. Axogen Inc now has $912.01M valuation. The stock increased 1.90% or $0.5 during the last trading session, reaching $26.75. About 141,089 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since February 14, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.
Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 18 analyst reports since August 11, 2015 according to SRatingsIntel. Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) on Thursday, November 2 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, November 22 by Lake Street. The stock has “Buy” rating by Cantor Fitzgerald on Monday, August 21. Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Monday, January 8. Cantor Fitzgerald has “Buy” rating and $37.0 target. Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Tuesday, November 21. Leerink Swann has “Outperform” rating and $30 target. Zacks upgraded AxoGen, Inc. (NASDAQ:AXGN) on Tuesday, August 11 to “Hold” rating. The firm earned “Buy” rating on Tuesday, November 21 by Wedbush. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Monday, November 7. Wedbush has “Outperform” rating and $12 target. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Monday, September 11 by Roth Capital. On Friday, August 28 the stock rating was maintained by Wedbush with “Outperform”.
Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on February, 28. They expect $-0.09 EPS, up 10.00% or $0.01 from last year’s $-0.1 per share. After $-0.06 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.
Lyon Street Capital Llc increased Century Cmntys Inc (NYSE:CCS) stake by 78,711 shares to 149,670 valued at $3.70M in 2017Q3. It also upped Natus Medical Inc Del (NASDAQ:BABY) stake by 62,107 shares and now owns 292,897 shares. Air Transport Services Grp I (NASDAQ:ATSG) was raised too.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $331.86 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.